Brief: Tenaya Therapeutics Launches Operations Of New Genetic Medicines Manufacturing Center To Support Development Of Potentially First-In-Class Cardiovascular Therapeutics
16/06/2022 13:09
June 16 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS LAUNCHES OPERATIONS OF NEW GENETIC
MEDICINES
MANUFACTURING CENTER TO SUPPORT THE DEVELOPMENT OF POTENTIALLY
FIRST-IN-CLASS CARDIOVASCULAR THERAPEUTICS
* TENAYA THERAPEUTICS INC - FACILITY TO PROVIDE CLINICAL
SUPPLY OF
LEAD GENE THERAPY PROGRAMS TN-201 AND TN-401 FOR PLANNED
FIRST-IN-HUMAN STUDIES
* TENAYA THERAPEUTICS INC - FACILITY HAS INITIAL PRODUCTION
CAPACITY AT 1000L SCALE
Source text for Eikon: ID:nBw29rgNDa
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027